Nephromag (Buffered Phosphate Solution | Mertiatide)

Buffered Phosphate Solution / Mertiatide, the active ingredient in Nephromag, is a buffered phosphate formulation presented as an intravenous solution for infusion use. It helps restore phosphate balance in patients requiring intravenous phosphate supplementation.

GNH USA supplies Nephromag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nephromag, a buffered phosphate solution, is used to manage disorders related to phosphate deficiency.

- Hypophosphatemia: correction of low serum phosphate levels in acute or chronic settings. - Renal replacement therapy: provides phosphate in dialysis fluids to maintain electrolyte balance. - Parenteral nutrition: supplies phosphate as part of total nutrient admixtures for patients unable to take oral intake.

Nephromag may be associated with a range of infusion‑related reactions.

Common Side Effects: - Transient hyperphosphatemia - Mild nausea - Headache - Infusion site irritation - Mild electrolyte shifts - Transient hypotension

Serious or Rare Side Effects: - Severe hyperphosphatemia leading to calcium‑phosphate precipitation - Anaphylactic or severe allergic reaction - Exacerbation of renal failure - Metabolic acidosis - Cardiac arrhythmia - Life‑threatening hypotension

When using Nephromag, clinicians should observe several safety measures.

- Dose adjustment: monitor serum phosphate and calcium levels during therapy. - Renal function: assess kidney function before and during infusion. - Cardiac status: watch for arrhythmias in patients with electrolyte disturbances. - Concurrent calcium therapy: avoid simultaneous high‑calcium infusion to prevent precipitation. - Pregnancy and lactation: use only if clearly needed and benefits outweigh potential risks. - Store at ambient temperature: keep in original container, protect from light and moisture.

Nephromag can interact with other agents that affect phosphate or calcium balance.

Major Interactions (Avoid): - Calcium‑containing solutions: risk of calcium‑phosphate precipitation. - Aluminum‑containing antacids: may bind phosphate and reduce efficacy. - High‑dose vitamin D analogues: can exacerbate hyperphosphatemia.

Moderate Interactions (Monitor Closely): - Loop diuretics: may alter electrolyte balance, requiring serum monitoring. - ACE inhibitors or ARBs: monitor renal function and phosphate levels. - Iron sucrose: may cause transient changes in phosphate concentrations.